¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"early mRNA"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 8 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • early ambulation
    Á¶±âº¸Çà
  • early antigen
    ÃʱâÇ׿ø
  • early cancer
    Á¶±â¾Ï
  • early fetal death
    Á¶±âžƻç¸Á
  • early neonatal mortality rate
    Á¶±â½Å»ý¾Æ»ç¸Á·ü
  • early receptor potential
    Á¶±â¼ö¿ëüÀüÀ§, Á¶±â½Ã°¢¼¼Æ÷ÀüÀ§
  • early syphilis
    Ãʱâ¸Åµ¶
  • early systolic murmur
    ¼öÃàÃʱâÀâÀ½
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • early ambulation
    Á¶±âº¸Çà
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 8 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • early antigen
    ÃʱâÇ׿ø
  • early cancer
    Á¶±â¾Ï
  • early fetal death
    Á¶±âžƻç¸Á
  • early reaction
    Á¶±â¹ÝÀÀ
  • early syphilis
    Ãʱâ¸Åµ¶, Á¶±â¸Åµ¶
  • early neonatal mortality rate
    ½Å»ý¾Æ»ç¸Á·ü
  • early receptor potential
    Á¶±â½Ã°¢¼¼Æ÷ÀüÀ§
  • early systolic murmur
    ¼öÃàÃʱâÀâÀ½
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • immediate early gene
    Á¶±â ¹ßÇö À¯ÀüÀÚ
  • polygenic mRNA
    ´ÙÀ¯ÀüÀÚ mRNA
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • early mRNA
    ÃʱâÃâÇö mRNA
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • polygenic mRNA
    ´ÙÀ¯ÀüÀÚ mRNA
  • amblyopia of early arrest
    Á¶±âÁ¤Áö¾à½Ã
  • early
    Á¶±â
  • early ambulation
    Á¶±â¿îµ¿½ÃÀÛ.
  • early ambulation
    Á¶±â¿îµ¿
  • early antigen
    ÃʱâÃâÇöÇ׿ø
  • early antigen
    Á¶±â Ç׿ø
  • early antigen
    ÃʱâÇ׿ø
  • early cancer
    Á¶±â¾Ï(ðÄÑ¢äß).
  • early cancer
    Á¶±â¾Ï(Á¶±â¾Ï).
  • early delivery
    Á¶±âºÐ¸¸.
  • early diagnosis
    Á¶±âÁø´Ü.
  • early diastolic murmur =protodiastolic m.
    Á¶±âÈ®ÀåÃʱâÀâÀ½(ðÄÑ¢üªíåôøÑ¢íÚëå).
  • early diastolic murmur =protodiastolic m.
    È®ÀåÃʱâ½ÉÀâÀ½.
  • early effect
    Á¶±âÈ¿°ú
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 14 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • early enzyme
    Á¶±â È¿¼Ò(ðÄÑ¢ý£áÈ)
  • early gene
    Á¶±â À¯ÀüÀÚ (ðÄÑ¢ë¶îîí­)
  • early protein
    Á¶±â ´Ü¹éÁú (ðÄÑ¢Ó±ÛÜòõ)
  • early RNA
    Á¶±â(ðÄÑ¢) RNA
  • immediate early RNA
    ÃÖÁ¶±â(õÌðÄÑ¢) RNA
  • very early RNA
    ÃÊÁ¶±â(õ±ðÄÑ¢) RNA
  • late mRNA
    ¸¸±â(عѢ) mRNA
  • masked mRNA
    ÀºÆó(ëßøÌ) mRNA
  • mRNA
    (å²) messenger RNA
  • mRNA coding triplet
    mRNA ÄÚµå»ïÁßÇ×(ß²ñìú£)
  • mRNA strand
    mRNA°¡´Ú
  • mt mRNA
    (å²) mitochondrial mRNA
  • pre-mRNA
    Àü±¸(îñÏÌ) mRNA
  • storage mRNA
    ÀúÀå(îÍíú) mRNA
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • early diagnosis
    Á¶±âÁø´Ü
  • early gastric cancer
    Á¶±âÀ§¾Ï
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
ED early-decision [applicant]; early differentiation; ectodermal dysplasia; ectopic depolarization; eff...
EMS early morning specimen; early morning stiffness; electrical muscle stimulation; Electronic Medical S...
mRNA messenger Ribo-Nucleic Acid
H-mRNA H-chain messenger ribonucleic acid
mRNA messenger ribonucleic acid
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
pre-mRNA Precursor mRNA
mRNA E-messenger RNA
mRNA Messenger ribonucleic acid
NMD Nonsense-mediated mRNA decay
mRNA RNA
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • amblyopia of early arrest
    Á¶±â Á¤Áö ¾à½Ã
  • early ambulation
    Á¶±â ¿îµ¿ ½ÃÀÛ
  • early assessment
    ÃÊ±â Æò°¡
  • early childhood
    Ãʱ⠾Ƶ¿±â
    ¸¸ 1-6¼¼ ±îÁöÀÇ ½Ã±â.
  • early clinical symptom
    Ãʱâ ÀÓ»ó Áõ»ó
  • early closing clicking joint noise
    Æó±¸ ÃʱâÀÇ ´Ü¼ø °üÀýÀâÀ½
    ÇÏ¾Ç °úµÎÀÇ ÈĹæ ȰÁÖ ¿îµ¿ Ãʱ⿡ ¹ß»ýÇÏ´Â °üÀýÀ½.
  • early diagnosis
    Á¶±â Áø´Ü
    º´ÀÇ ÁøÇà¿¡ ¾Õ¼­ Áø´ÜÇÏ¿© ´ëÃ¥À» ¼¼¿ò, ¿ÏÀü Ä¡À¯ ±â´ë.
  • early distal tubule
    Ãʱ⠿øÀ§ ¼¼´¢°ü
  • early gestation
    ÀӽŠÃʱâ
  • early melanoma
    Ãʱâ Èæ»öÁ¾
    ¸á¶ó´Ñ ¼¼Æ÷ÀÇ ¾Ç¼º Á¾¾ç¿¡ Ãʱ⠴ܰè. Á¾Á¾ ¾ç¼º ¸ð¹ÝÀ¸·Î ¿ÀÇØµÈ´Ù. ±¸°­¿¡¼­ °¡Àå ÈçÇÑ Èæ»öÁ¾Àº Ç¥Ãþ È®À强 Èæ»öÁ¾, °áÀý¼º Èæ»öÁ¾, ¸»´ÜÈæ»öÁ¾À¸·Î ³ª´µ¾îÁø´Ù. ¿¹Èİ¡ ³ª»Ú´Ù.
  • early nodular melanoma
    Ãʱ⠼ҰáÀý¼º Èæ»öÁ¾
  • early opening clicking joint noise
    °³±¸ ÃʱâÀÇ ´Ü¼ø °üÀýÀâÀ½
    ÇÏ¾Ç °úµÎÀÇ Àü¹æ ȰÁֿ Ãʱ⿡ ¹ß»ýÇÏ´Â °üÀýÀ½.
  • early petechiae
    Ãʱâ Á¡»ó ÃâÇ÷
  • early postprandial postgastrectomy syndrome
    Á¶±â ½ÄÈļº À§ ÀýÁ¦ ÈÄ ÁõÈıº
  • early primary closure
    Á¶±â 1Â÷ ºÀÇÕ
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
alternative mRNA splicing Splicing different exons in or out of messenger RNA to form different mRNA transcripts.
(09 Oct 1997)
capping of mRNA The process of adding a guanosine nucleotide to the 5'-end (the beginning) of an eukaryotic mRNA, then methylating (adding a -CH3 to) the guanosine.
(09 Oct 1997)
maternal mRNA <molecular biology> Messenger RNA found in oocytes and early embryos that is derived from the maternal genome during oogenesis.
See: masked messenger RNA.
(18 Nov 1997)
mRNA <molecular biology> Single stranded RNA molecule that specifies the amino acid sequence of one or more polypeptide chains. This information is translated during protein synthesis when ribosomes bind to the mRNA.
In prokaryotes, mRNA is normally formed by splicing a large primary transcript from a DNA sequence and protein synthesis starts while the mRNA is still being synthesised. Prokaryote mRNAs are usually very short lived (average t 1/2 is 5mins.).
In contrast, in eukaryotes the primary transcripts (HnRNA) are synthesised in the nucleus and they are extensively processed to give the mRNA that is exported to the cytoplasm where protein synthesis takes place.
This processing includes the addition of a 5' 5' linked 7 methyl guanylate cap at the 5' end and a sequence of adenylate groups at the 3' end, the poly A tail, as well as the removal of any introns and the splicing together of exons, only 10% of HnRNA leaves the nucleus.
Eukaryote mRNAs are comparatively long lived with a half life ranging from 30minutes to 24 hours.
(27 Jun 1999)
mRNA (2'-O-methyladenosine-N6-)-methyltransferase <enzyme> Involved in capping mRNA
Registry number: EC 2.1.1.62
Synonym: mRNA n(6)-adenosine methyltransferase, mra methyltransferase, RNA(2'-o-methyladenosine-n(6)-)methyltransferase
(26 Jun 1999)
mRNA(adenine-N6)-methyltransferase <enzyme> Methylates mRNA at internal adenosine within the consensus sequence puac(a/c/u)
Registry number: EC 2.1.1.-
Synonym: mRNA-a-n6-methyltransferase, mRNA(adenine-n6)-methylase
(26 Jun 1999)
mRNA (guanine(N7))-methyltransferase <enzyme> Catalyses s-adenosyl-l-methionine and g(5')pppr-RNA to yield s-adenosyl-l-homocysteine and m(7)g(5')pppr-RNA; mRNA containing an n(7)-methylguanine cap
Registry number: EC 2.1.1.56
Synonym: mRNA (guanine-7-)methyltransferase, mRNA(guanine-7-)methyltransferase, RNA (guanine-7) methyltransferase, abd1 gene product
(26 Jun 1999)
mRNA guanylyltransferase <enzyme> Catalyses transfer of GMP residue from GTP to 5' end of RNA to form cap structure identified as g(5')pppn; can also modify synthetic poly(a) and poly(g) to form m7g(5')pppan and m7g(5')pppgn; see also capping enzyme, vaccinia virus
Registry number: EC 2.7.7.50
Synonym: RNA guanylyltransferase, m-RNA guanylyltransferase, GTP mRNA guanylyltransferase, mRNA capping enzyme, mRNA 5'-guanylyltransferase, cgt1 gene product, ceg1 gene product
(26 Jun 1999)
mRNA maturase <enzyme> Also potent endonuclease involved in recombination
Registry number: EC 2.7.7.-
Synonym: RNA, mitochondrial maturase, RNA maturase
(26 Jun 1999)
mRNA (nucleoside-O(2'))-methyltransferase <enzyme> Catalyses the reaction of s-adenosyl-l-methionine and m(7)g(5')pppr-RNA to yield s-adenosyl-l-homocysteine and m(7)g(5')ppprm-RNA; mRNA containing an o(2')-methylpurine cap
Registry number: EC 2.1.1.57
(26 Jun 1999)
polycistronic mRNA <molecular biology> A single mRNA molecule that is the product of the transcription of several tandemly arranged genes, typically the mRNA transcribed from an operon.
(18 Nov 1997)
6-methyladenine mRNA methyltransferase <enzyme> Forms internal n6-methyladenine residues
Registry number: EC 2.1.1.-
Synonym: m6a mRNA methyltransferase
(26 Jun 1999)
adenovirus early proteins <molecular biology, protein, virology> Proteins encoded by adenoviruses that are synthesised prior to, and in the absence of, viral DNA replication.
The proteins are involved in both positive and negative regulation of expression in viral and cellular genes, and also affect the stability of viral mRNA. Some are also involved in oncogenic transformation.
(12 Dec 1998)
genes, immediate-early Genes that show rapid and transient expression in the absence of de novo protein synthesis. The term was originally used exclusively for viral genes where immediate-early referred to transcription immediately following virus integration into the host cell. It is also used to describe cellular genes which are expressed immediately after resting cells are stimulated by extracellular signals such as growth factors and neurotransmitters.
(12 Dec 1998)
history of medicine, early modern The period of the history of medicine from 1451 through 1600 a.d. History of medicine, 15th cent. And history of medicine, 16th cent. Are also available.
(12 Dec 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • early
    À̸¥,°¡±î¿î Àå·¡ÀÇ,»¡¸®,Ãʱ⿡
  • Distant Early Warning line
    =DEW LINE
  • Early Bird
    ¹Ì±¹ÀÇ »ó¾÷ Åë½Å À§¼º(ºÏ¹Ì¿Í À¯·´°£ÀÇ)
  • Early English
    Ãʱ⠿µ¾î
  • Early English style
    Ãʱ⠿µ±¹ÀÇ °ÇÃà ¾ç½Ä
  • Early Modern English
    ÃÊ±â ±Ù´ë ¿µ¾î
  • early
    À̸¥;ÃʱâÀÇ;ÀϵǴÂ;¸º¹°ÀÇ;¾î¸±¶§ÀÇ;°¡±î¿î Àå·¡ÀÇ(at an early date)±Ý¸í°£¿¡;¸ÓÁö ¾Ê¾Æ;ÀÏÂïÀÚ°í ÀÏÂï ÀϾ´Ù(keep early hours);ÀÏÂï;À̸¥ ¶§¿¡;Ãʱ⿡
  • early Victorian
    ºòÅ丮¾Æ ¿ÕÁ¶ ÃʱâÀÇ(»ç¶÷(ÀÛ°¡));±¸½ÄÀÇ(»ç¶÷)
  • early bird
    (±¸)À̸¥ ¾ÆÄ§ÀÇ;ÀÏÂï ¿À´Â »ç¶÷À» À§ÇÑ
  • early bird
    ÀÏÂï ÀϾ´Â »ç¶÷;Á¤ÇÑ ½Ã°¢º¸´Ù ÀÏÂï ¿À´Â »ç¶÷
  • early closing
    °³Á¡ ½Ã°£ ´ÜÃà(ÀÏ)
  • early door
    Ưº° ÃâÀÔ±¸(Ưº° ¿ä±ÝÀ¸·Î Á¤°¢º¸´Ù »¡¸® ÀÔÀå½ÃŰ´Â ¹®)
  • early leaver
    (¿µ)(Çб³ÀÇ)Áßµµ ÅðÇÐÀÚ;³«¿ÀÀÚ
  • early warning
    (¹æ°ø µîÀÇ)Á¶±â °æº¸
  • early-to-bedder
    ÀÏÂï ÀÚ´Â »ç¶÷
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á